- Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical validation needed to determine the program’s next development steps.
- VXA-222 uses an “AND-gate” approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload.
- The company has separately filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms while expanding protection around antibody conjugation and payload technologies.
- The company is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has moved its VXA-222 bispecific antibody-drug conjugate program into the next stage of development after completing the initial phase of its collaboration with OmniAb, giving the biotechnology company a new development milestone while it continues expanding the intellectual-property estate underpinning its antibody technology portfolio.
Questions around this news
What work is planned for VXA-222 after the OmniAb collaboration phase?
The release says VERAXA plans to use antibody binders produced during the collaboration to create the final VXA-222 candidate. It also expects to carry out preclinical validation, which will help inform what development steps follow. The release does not provide a schedule or describe what those later steps will be.
How is VXA-222’s AND-gate approach intended to work?
The release describes VXA-222 as designed to respond to two tumor-associated antigens at once before releasing its therapeutic payload. This is intended to make recognition depend on both signals rather than either one alone. The release does not identify the antigens or provide experimental results demonstrating how the approach performs.
What is an antibody-drug conjugate?
An antibody-drug conjugate links an antibody to a drug or other therapeutic payload. The antibody is designed to bind a chosen target, while the attached payload provides the treatment effect. Researchers study how the components behave together, including whether the conjugate reaches target cells and releases its payload as intended.
What intellectual-property activity does the release describe?
The release says the company has filed its first patents concerning its BiTAC-TCE and BiTAC-ADC platforms. It also reports continued efforts to broaden protection related to antibody conjugation and payload technologies. It does not specify the patent claims, jurisdictions, or status of any patent applications.
According to a Yahoo Finance report, VERAXA will now take the antibody binders generated through the OmniAb collaboration and use its own antibody engineering, linker and conjugation technologies to construct the final…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- VERAXA Biotech
- Ticker
- NASDAQ: VRXA
- Announcement
- Product
Products and programs
SEC filings
- 4FORM 4 Filed
- 4FORM 4 Filed
- 6-KReport of a foreign issuer Filed
- 3FORM 3 Filed
- SCHEDULE 13G/ASCHEDULE 13G/A Filed
- 424B5Prospectus supplement Filed
- 424B5Prospectus supplement Filed
- EFFECTEFFECT Filed
- EFFECTEFFECT Filed
- F-1/AF-1/A Filed
- F-1/AF-1/A Filed
- F-1F-1 Filed
- F-1F-1 Filed
- 6-KReport of a foreign issuer Filed
- 6-KReport of a foreign issuer Filed
Earlier from VERAXA Biotech
- VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision
- VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
- VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
- VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
- VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
